Successful Treatment of a B/T MPAL Patient by Chemo-free Treatment with Venetoclax, Azacitidine, and Blinatumomab

Overview

Journal Ann Hematol

Specialty Hematology

Date 2024 Feb 17

PMID 38367057

Authors

Shaoyu Liu

Qingya Cui

Mengyun Li

Zheng Li

Sifan Chen

Depei Wu

Xiaowen Tang

Affiliations

Soon will be listed here.

Abstract

B/T mixed phenotype acute leukemia (MPAL), which represents only 2-3% of all MPAL cases, is classified as a high-risk leukemia subtype. Adults diagnosed with B/T MPAL have a notably low 3-year survival rate, estimated at 20-40%. The rarity and undercharacterization of B/T MPAL present substantial challenges in identifying an optimal treatment protocol. This report aims to shed light on this issue by presenting a case in which a patient with a complex karyotype was treated using a combination of venetoclax, azacitidine, and blinatumomab. This novel, chemo-free regimen resulted in the patient achieving both hematologic and molecular complete remission, with no severe organ or hematological toxicity observed. Notably, the patient continued to maintain molecular remission for 1 year following the transplantation. Based on these findings, the combination of venetoclax, azacitidine, and blinatumomab could be considered a potential therapeutic approach for B/T MPAL patients, meriting further investigation.

References

Matutes E, Pickl W, Veer M, Morilla R, Swansbury J, Strobl H . Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification. Blood. 2011; 117(11):3163-71. DOI: 10.1182/blood-2010-10-314682. View

Weinberg O, Arber D . Mixed-phenotype acute leukemia: historical overview and a new definition. Leukemia. 2010; 24(11):1844-51. DOI: 10.1038/leu.2010.202. View

Gerr H, Zimmermann M, Schrappe M, Dworzak M, Ludwig W, Bradtke J . Acute leukaemias of ambiguous lineage in children: characterization, prognosis and therapy recommendations. Br J Haematol. 2010; 149(1):84-92. DOI: 10.1111/j.1365-2141.2009.08058.x. View

Alexander T, Gu Z, Iacobucci I, Dickerson K, Choi J, Xu B . The genetic basis and cell of origin of mixed phenotype acute leukaemia. Nature. 2018; 562(7727):373-379. PMC: 6195459. DOI: 10.1038/s41586-018-0436-0. View

Rubnitz J, Onciu M, Pounds S, Shurtleff S, Cao X, Raimondi S . Acute mixed lineage leukemia in children: the experience of St Jude Children's Research Hospital. Blood. 2009; 113(21):5083-9. PMC: 2686179. DOI: 10.1182/blood-2008-10-187351. View

Maruffi M, Sposto R, Oberley M, Kysh L, Orgel E . Therapy for children and adults with mixed phenotype acute leukemia: a systematic review and meta-analysis. Leukemia. 2018; 32(7):1515-1528. PMC: 7508489. DOI: 10.1038/s41375-018-0058-4. View

Rasekh E, Osman R, Ibraheem D, Madney Y, Radwan E, Gameel A . Acute lymphoblastic leukemia-like treatment regimen provides better response in mixed phenotype acute leukemia: a comparative study between adults and pediatric MPAL patients. Ann Hematol. 2020; 100(3):699-707. DOI: 10.1007/s00277-020-04354-2. View

Beldjord K, Chevret S, Asnafi V, Huguet F, Boulland M, Leguay T . Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. Blood. 2014; 123(24):3739-49. DOI: 10.1182/blood-2014-01-547695. View

Liu K, Li Y, Qiu S, Zhou C, Wei S, Lin D . Efficacy of combination of venetoclax with azacitidine or chemotherapy in refractory/relapse acute leukemias of ambiguous lineage, not otherwise specified. Exp Hematol Oncol. 2021; 10(1):46. PMC: 8447663. DOI: 10.1186/s40164-021-00239-w. View

10.

Seymour J, Kipps T, Eichhorst B, Hillmen P, DRozario J, Assouline S . Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. N Engl J Med. 2018; 378(12):1107-1120. DOI: 10.1056/NEJMoa1713976. View

11.

DiNardo C, Pratz K, Pullarkat V, Jonas B, Arellano M, Becker P . Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2018; 133(1):7-17. PMC: 6318429. DOI: 10.1182/blood-2018-08-868752. View

12.

DiNardo C, Jonas B, Pullarkat V, Thirman M, Garcia J, Wei A . Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N Engl J Med. 2020; 383(7):617-629. DOI: 10.1056/NEJMoa2012971. View

13.

Aumann S, Shaulov A, Haran A, Even-Zohar N, Vainstein V, Nachmias B . The Emerging Role of Venetoclax-Based Treatments in Acute Lymphoblastic Leukemia. Int J Mol Sci. 2022; 23(18). PMC: 9504828. DOI: 10.3390/ijms231810957. View

14.

Gibson A, Trabal A, McCall D, Khazal S, Toepfer L, Bell D . Venetoclax for Children and Adolescents with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Cancers (Basel). 2022; 14(1). PMC: 8750927. DOI: 10.3390/cancers14010150. View

15.

Kantarjian H, Stein A, Gokbuget N, Fielding A, Schuh A, Ribera J . Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. N Engl J Med. 2017; 376(9):836-847. PMC: 5881572. DOI: 10.1056/NEJMoa1609783. View

16.

Gokbuget N, Dombret H, Bonifacio M, Reichle A, Graux C, Faul C . Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2018; 131(14):1522-1531. PMC: 6027091. DOI: 10.1182/blood-2017-08-798322. View

17.

Munker R, Brazauskas R, Wang H, de Lima M, Khoury H, Gale R . Allogeneic Hematopoietic Cell Transplantation for Patients with Mixed Phenotype Acute Leukemia. Biol Blood Marrow Transplant. 2016; 22(6):1024-1029. PMC: 4867266. DOI: 10.1016/j.bbmt.2016.02.013. View

18.

Tian H, Xu Y, Liu L, Yan L, Jin Z, Tang X . Comparison of outcomes in mixed phenotype acute leukemia patients treated with chemotherapy and stem cell transplantation versus chemotherapy alone. Leuk Res. 2016; 45:40-6. DOI: 10.1016/j.leukres.2016.04.002. View